Literature DB >> 4175670

Phosphate treatment of hypercalcaemia due to carcinoma.

N Thalassinos, G F Joplin.   

Abstract

Thirteen patients with hypercalcaemia due to carcinoma received inorganic phosphate, orally or intravenously, as palliative treatment for their high serum calcium levels. The serum calcium promptly fell in all patients fully treated, and there was a striking clinical improvement in most patients. The blood urea was usually unchanged or became nearer to normal, while the serum phosphate altered variably. Only two of the eight patients who were studied at necropsy had microscopical nephrocalcinosis; corneal calcification was evident in both before phosphate treatment was started.This oral inorganic phosphate (1 gramme thrice daily) is a safe and effective means of treating hypercalcaemia due to carcinoma. An intravenous infusion of 1 gramme over eight hours may sometimes be required initially for patients who are vomiting.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4175670      PMCID: PMC1912048          DOI: 10.1136/bmj.4.5622.14

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  18 in total

1.  Hypercalcemia and renal insufficiency due to sarcoidosis: treatment with cortisone.

Authors:  W J GLECKLER
Journal:  Ann Intern Med       Date:  1956-01       Impact factor: 25.391

2.  Hypercalcemia in malignant disease without evidence of bone destruction.

Authors:  A GELLHORN; C H PLIMPTON
Journal:  Am J Med       Date:  1956-11       Impact factor: 4.965

3.  Hypercalcemia, a complication of hormone therapy of advanced breast cancer.

Authors:  B J KENNEDY; D M TIBBETTS; I T NATHANSON; J C AUB
Journal:  Cancer Res       Date:  1953-06       Impact factor: 12.701

4.  Removal of calcium in man by ethylenediamine tetra-acetic acid. A metabolic study.

Authors:  H SPENCER; V VANKINSCOTT; I LEWIN; D LASZLO
Journal:  J Clin Invest       Date:  1952-12       Impact factor: 14.808

5.  THE FUNCTIONAL PATHOLOGY OF HYPER-PARATHYROIDISM.

Authors:  H A Bulger; H H Dixon; D P Barr; O Schregardus
Journal:  J Clin Invest       Date:  1930-08       Impact factor: 14.808

6.  STUDIES IN PARATHYROID PHYSIOLOGY: III. The Effect of Phosphate Ingestion in Clinical Hyperparathyroidism.

Authors:  F Albright; W Bauer; D Claflin; J R Cockrill
Journal:  J Clin Invest       Date:  1932-03       Impact factor: 14.808

7.  Alkeran (Melphalan) in the treatment of myelomatosis.

Authors:  A Drivsholm; A Videbaek
Journal:  Acta Med Scand Suppl       Date:  1966

8.  Treatment of hypercalcemia with inorganic phosphate.

Authors:  H J Kistler
Journal:  Helv Med Acta       Date:  1967-08

9.  Hypernatremia complicating sodium sulfate therapy for hypercalcemic crisis.

Authors:  B A Heckman; J H Walsh
Journal:  N Engl J Med       Date:  1967-05-11       Impact factor: 91.245

10.  Studies of the mechanism by which phosphate infusion lowers serum calcium concentration.

Authors:  L A Hebert; J Lemann; J R Petersen; E J Lennon
Journal:  J Clin Invest       Date:  1966-12       Impact factor: 14.808

View more
  6 in total

1.  Hormones in advanced cancer.

Authors: 
Journal:  Br Med J       Date:  1971-06-26

2.  An acceptable slow-release phosphate preparation "slow P".

Authors:  V Parsons; A Porter; C Lund
Journal:  Postgrad Med J       Date:  1970-07       Impact factor: 2.401

3.  [Phosphate treatment in hypercalcemia].

Authors:  H J Kistler; W Neubauer
Journal:  Klin Wochenschr       Date:  1970-06-15

4.  Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors.

Authors:  Tariq Chukir; Yi Liu; Katherine Hoffman; John P Bilezikian; Azeez Farooki
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

Review 5.  Medical management of hypercalcaemia.

Authors:  S H Ralston
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

6.  Hypercalcaemia in patients with advanced mammary cancer.

Authors:  C S Galasko; J I Burn
Journal:  Br Med J       Date:  1971-09-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.